Rolapitant - TESARO

Drug Profile

Rolapitant - TESARO

Alternative Names: Rolapitant hydrochloride; SCH-619734; VARUBI; Varuby

Latest Information Update: 06 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; Schering-Plough; TESARO
  • Class Antiemetics; Ethers; Piperidines; Pyrrolidines; Small molecules; Spiro compounds
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • Discontinued Cough; Postoperative nausea and vomiting

Most Recent Events

  • 28 Jun 2018 Rolapitant sub-licensed to TerSera Therapeutics in USA and Canada
  • 12 Jan 2018 TESARO in collaboration with the US FDA announces changes to rolapitant (VARUBI®) package insert to include modifications to the Contraindication, Warnings and Precautions, and Adverse reactions sections
  • 28 Nov 2017 Launched for Chemotherapy induced nausea and vomiting (Combination therapy, Prevention) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top